Enlivex Therapeutics Return on Equity

Enlivex Therapeutics's return on equity stands at 105.35%. That is above the Healthcare sector average of 20.77%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Enlivex Therapeutics sits higher the Healthcare benchmark (20.77%) with a ROE of 105.35%. That is roughly 407.3% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of 105.35% for Enlivex Therapeutics means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Enlivex Therapeutics's ROE evolved across reporting periods, while the comparison chart places ENLV next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, ROE is commonly used to spot outliers. Enlivex Therapeutics's reading of 105.35% (sector avg 20.77%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.